Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 15, 2018 16:01 ET | Source: Gemphire Therapeutics Inc.

Gemphire Therapeutics Reports Fourth Quarter and Fiscal Year 2017 Financial Results

Conference Call & Live Webcast Today at 4:30pm Eastern Time LIVONIA, Mich., March 15, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical...
March 13, 2018 09:18 ET | Source: Gemphire Therapeutics Inc.

Gemphire Therapeutics to Announce Fourth Quarter and Year End 2017 Financial Results on Thursday, March 15

LIVONIA, Mich., March 13, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for...
March 08, 2018 08:00 ET | Source: Gemphire Therapeutics Inc.

Gemphire to Present at Two Investor Conferences

LIVONIA, Mich., March 08, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for...
February 27, 2018 16:01 ET | Source: Gemphire Therapeutics Inc.

Gemphire Expert Panel Call on Pediatric Nonalcoholic Fatty Liver Disease (NAFLD) and NASH to be Rescheduled

LIVONIA, Mich., Feb. 27, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for...
February 21, 2018 06:00 ET | Source: Gemphire Therapeutics Inc.

Gemphire to Host Expert Panel Call to Discuss Pediatric Nonalcoholic Fatty Liver Disease (NAFLD) and NASH

LIVONIA, Mich., Feb. 21, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for...
February 08, 2018 09:00 ET | Source: Gemphire Therapeutics Inc.

Gemphire Announces Pricing of $22 Million Public Offering of Common Stock

LIVONIA, Mich., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for...
February 07, 2018 16:32 ET | Source: Gemphire Therapeutics Inc.

Gemphire Announces Proposed Public Offering of Common Stock

LIVONIA, Mich., Feb. 07, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for...
January 31, 2018 16:01 ET | Source: Gemphire Therapeutics Inc.

Gemphire Announces Initiation of Phase 2a Clinical Trial of Gemcabene in Pediatric Non-Alcoholic Fatty Liver Disease (NAFLD)

Pediatric NAFLD/NASH is a large and untreated market; provides an opportunity to advance gemcabene in an underserved area with millions of affected patients Proof-of-concept clinical trial expands...
January 17, 2018 06:30 ET | Source: Gemphire Therapeutics Inc.

Gemphire Completes Patient Enrollment in INDIGO-1 Trial in Severe Hypertriglyceridemia (SHTG) Patients

On Track to Report Top-Line Data from Phase 2b Trial in Second Quarter of 2018 LIVONIA, Mich., Jan. 17, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage...
December 21, 2017 06:00 ET | Source: Gemphire Therapeutics Inc.

Gemphire Therapeutics Announces Initiation of its First NASH Proof-of-Concept Clinical Trial and its Differentiated NASH Program

Phase 2a trial will investigate gemcabene in Familial Partial Lipodystrophy (FPL) – a rare genetic disease with characteristic presentation of cardiovascular disease and NASH Gemcabene has a...